Overview
ANI Q3 2025 revenue grows 53.6% yr/yr, beating analyst expectations
Adjusted EPS for Q3 2025 beats consensus, reaching $2.04
Company raises 2025 revenue and adjusted EBITDA guidance, citing strong Rare Disease growth
Outlook
ANI raises 2025 total net revenue guidance to $854 mln - $873 mln
Company expects Rare Disease net revenues to be 50% of total in 2025
ANI anticipates 2025 adjusted non-GAAP EBITDA of $221 mln - $228 mln
Result Drivers
CORTROPHIN GEL GROWTH - Cortrophin Gel net revenues increased 93.8% yr/yr due to increased demand and expanded sales force across specialties
ILUVIEN REVENUE PRESSURE - ILUVIEN net revenues were pressured by reduced Medicare access but showed progress in label transition adoption
GENERICS GROWTH - Generics net revenues increased 20.6% yr/yr driven by a successful partnered generic launch
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $227.80 mln | $211.04 mln (8 Analysts) |
Q3 Adjusted EPS | Beat | $2.04 | $1.75 (8 Analysts) |
Q3 EPS | $1.13 | ||
Q3 Net Income | $26.30 mln | ||
Q3 Adjusted EBITDA | $59.60 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for ANI Pharmaceuticals Inc is $103.00, about 12.4% above its November 6 closing price of $90.23
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 9 three months ago
Press Release: ID:nGNX60lmXM
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)